We hypothesize that variance in transfusion practice for patients on ECMO is high.
ID
Bron
Verkorte titel
Aandoening
ECMO is indicated in case of potentially reversible cardio(respiratory) failure refractory to conventional therapies. It can be divided in two main groups: the respiratory indications (e.g. acute respiratory distress syndrome), for which veno-venous ECMO is indicated; and isolated cardiac or combined cardiorespiratory failure (e.g. acute myocardial infarction), for which veno-arterial ECMO is indicated. It is a vulnerable population in the ICU, for which ECMO often functions as a “last resort” therapy.
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The primary outcome is the total and daily amount of transfusion of blood products (red blood cells, platelets, plasma) and tranexamic acid, fibrinogen and prothrombin complex concentrate, received by patients on ECMO up to 28 days of support. Furthermore, clinical variables that may be associated with the occurrence of transfusion and a higher amount of transfusions will be evaluated.
Achtergrond van het onderzoek
Extracorporeal life support (ECLS), also referred to as extracorporeal membrane oxygenation (ECMO), is used as a supportive method in case of temporary and potentially reversible cardio(respiratory) failure refractory to conventional therapies. Currently, for patients on ECMO, thresholds for transfusion of red blood cells, platelets, plasma and coagulating agents such as fibrinogen are only based on expert opinion. Several single-center retrospective studies show that many patients on ECMO receive many transfusions. However, these studies are based on a single-center and have small sample sizes. The aim of this study is to give an overview in patients on ECMO of the amount of transfusion of blood products (red blood cells, plasma and platelets) and administration of fibrinogen, tranexamic acid and prothrombin complex concentrate.
Doel van het onderzoek
We hypothesize that variance in transfusion practice for patients on ECMO is high.
Onderzoeksopzet
N/A
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Patients were included in the study if:
- They were admitted to the Intensive Care Unit (ICU) between January 1st 2018 up to July 1st 2019; AND
- They received support from extracorporeal membrane oxygenation (ECMO) during their ICU admission; AND
- They were aged 18 years and older.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
Patients were excluded in the study if:
- The total duration of ECMO support was less than 24 hours.
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL8413 |
| Ander register | METC AMC : W19_222 # 19.267 |